AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
ferric oxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4443 | 1309-37-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A glucaric acid-iron conjugate that is used in the treatment of IRON-DEFICIENCY ANEMIA, including in patients with chronic kidney disease, when oral iron therapy is ineffective or impractical.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 59 | |||
| kinase-selectivity-class | GRK2,MAP2K6,PIK3CG,TEK | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V08CB03 | VARIOUS CONTRAST MEDIA MAGNETIC RESONANCE IMAGING CONTRAST MEDIA Superparamagnetic contrast media |
| MeSH PA | D006397 | Hematinics |
| MeSH PA | D006401 | Hematologic Agents |
Related Drugs by ATC class:
V08CB Superparamagnetic contrast media 1 drug
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Proctitis | indication | 3951002 | DOID:3127 |
| Wound | indication | 13924000 | |
| Anemia of prematurity | indication | 47100003 | DOID:11243 |
| Burn injury | indication | 48333001 | |
| Hemorrhoids | indication | 70153002 | DOID:9746 |
| Rectal pain | indication | 77880009 | |
| Iron deficiency anemia | indication | 87522002 | |
| Eruption of skin | indication | 271807003 | DOID:0050486 |
| Arthropod bite wound | indication | 409985002 | |
| Itching of skin | indication | 418363000 | |
| Hemosiderosis | contraindication | 39011001 | DOID:12119 |
| Low blood pressure | contraindication | 45007003 | |
| Chronic Iron Overload | contraindication |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Swine | Anemia caused by iron deficiency | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Felac | Zoetis Inc. | 1 |
| Optimmune | Intervet Inc. | 1 |
| Atopica | Elanco US Inc. | 1 |
| Sporimune | Dechra Veterinary Products LLC | 1 |
| CYCLAVANCE | Virbac AH Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D04616 | KEGG_DRUG |
| 4020222 | VUID |
| N0000179132 | NUI |
| 4020161 | VANDF |
| 4020162 | VANDF |
| 4020222 | VANDF |
| CHEBI:753477 | CHEBI |
| CHEMBL2108514 | ChEMBL_ID |
| DB11576 | DRUGBANK_ID |
| C000499 | MESH_SUPPLEMENTAL_RECORD_UI |
| 518696 | PUBCHEM_CID |
| 1310572 | RXNORM |
| NOCODE | MMSL |
| 006622 | NDDF |
| 006623 | NDDF |
| C0060240 | UMLSCUI |
| D000077605 | MESH_DESCRIPTOR_UI |
| 129497004 | SNOMEDCT_US |
| 387206004 | SNOMEDCT_US |
| 421953007 | SNOMEDCT_US |
| 1K09F3G675 | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Caladryl | HUMAN OTC DRUG LABEL | 3 | 0187-5465 | LOTION | 1.36 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Walgreens CalamineSkin Protectant | HUMAN OTC DRUG LABEL | 2 | 0363-4360 | LOTION | 8 mL | TOPICAL | OTC monograph final | 12 sections |
| Calamine Plus Pramoxine HCl | HUMAN OTC DRUG LABEL | 3 | 0363-8588 | AEROSOL, SPRAY | 0.35 mg | TOPICAL | OTC Monograph Drug | 12 sections |
| Calamine Plus Pramoxine HCl | HUMAN OTC DRUG LABEL | 3 | 0363-8588 | AEROSOL, SPRAY | 0.35 mg | TOPICAL | OTC Monograph Drug | 12 sections |
| Calamine | HUMAN OTC DRUG LABEL | 2 | 0904-2533 | LOTION | 80 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| Calamine | HUMAN OTC DRUG LABEL | 2 | 11344-063 | LOTION | 80 mg | TOPICAL | OTC Monograph Drug | 12 sections |
| Calamine | HUMAN OTC DRUG LABEL | 2 | 11344-136 | LOTION | 80 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| Calamine | HUMAN OTC DRUG LABEL | 2 | 11673-063 | LOTION | 80 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| LanoguardMulti-Purpose | HUMAN OTC DRUG LABEL | 3 | 12090-0061 | OINTMENT | 20 mg | TOPICAL | OTC monograph final | 11 sections |
| Calamine | HUMAN OTC DRUG LABEL | 2 | 21130-941 | LOTION | 80 mg | TOPICAL | OTC Monograph Drug | 12 sections |
| Calamine | HUMAN OTC DRUG LABEL | 2 | 30142-063 | LOTION | 8 g | TOPICAL | OTC Monograph Drug | 13 sections |
| Calamine Plus Pramoxine HCl | HUMAN OTC DRUG LABEL | 3 | 30142-156 | AEROSOL, SPRAY | 0.35 mg | TOPICAL | OTC Monograph Drug | 12 sections |
| Calamine Plus Pramoxine HCl | HUMAN OTC DRUG LABEL | 3 | 30142-156 | AEROSOL, SPRAY | 0.35 mg | TOPICAL | OTC Monograph Drug | 12 sections |
| Calamine Plus | HUMAN OTC DRUG LABEL | 3 | 30142-429 | SPRAY | 0.40 mg | TOPICAL | OTC Monograph Drug | 12 sections |
| MAYINGLONG BEZORNIL HEMORRHOIDAL | HUMAN OTC DRUG LABEL | 4 | 30803-001 | OINTMENT | 0.05 g | TOPICAL | OTC monograph final | 15 sections |
| Calamine | HUMAN OTC DRUG LABEL | 2 | 36800-063 | LOTION | 80 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| Calamine Plus Pramoxine HCl | HUMAN OTC DRUG LABEL | 3 | 36800-398 | AEROSOL, SPRAY | 0.35 mg | TOPICAL | OTC Monograph Drug | 11 sections |
| Calamine Plus Pramoxine HCl | HUMAN OTC DRUG LABEL | 3 | 36800-398 | AEROSOL, SPRAY | 0.35 mg | TOPICAL | OTC Monograph Drug | 11 sections |
| Calamine, Pramoxind HCl | HUMAN OTC DRUG LABEL | 2 | 37808-616 | LOTION | 80 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Calamine, Zinc Oxide | HUMAN OTC DRUG LABEL | 2 | 37808-621 | LOTION | 80 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| Calamine | HUMAN OTC DRUG LABEL | 2 | 41163-536 | LOTION | 80 mg | TOPICAL | OTC Monograph Drug | 12 sections |
| Calamine Plus Pramoxine HCl | HUMAN OTC DRUG LABEL | 3 | 41520-184 | AEROSOL, SPRAY | 0.35 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| Calamine Plus Pramoxine HCl | HUMAN OTC DRUG LABEL | 3 | 42507-147 | AEROSOL, SPRAY | 0.35 mg | TOPICAL | OTC monograph not final | 11 sections |
| Calamine Plus Pramoxine HCl | HUMAN OTC DRUG LABEL | 3 | 42507-956 | AEROSOL, SPRAY | 5 mg | TOPICAL | OTC Monograph Drug | 12 sections |
| Calamine Plus | HUMAN OTC DRUG LABEL | 3 | 46122-745 | AEROSOL, SPRAY | 0.35 mg | TOPICAL | OTC Monograph Drug | 12 sections |
| Calamine Plus | HUMAN OTC DRUG LABEL | 3 | 46122-745 | AEROSOL, SPRAY | 0.35 mg | TOPICAL | OTC Monograph Drug | 12 sections |
| Calamine | HUMAN OTC DRUG LABEL | 2 | 46122-809 | LOTION | 80 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| Calamine Plus | HUMAN OTC DRUG LABEL | 3 | 49035-030 | AEROSOL, SPRAY | 0.35 mg | TOPICAL | OTC Monograph Drug | 12 sections |
| REMEDY Calazime Skin Protectant | HUMAN OTC DRUG LABEL | 4 | 53329-165 | PASTE | 0.50 g | TOPICAL | OTC Monograph Drug | 13 sections |
| Dermagesic | HUMAN OTC DRUG LABEL | 3 | 54859-120 | LIQUID | 0.40 mg | TOPICAL | OTC Monograph Drug | 10 sections |